Suppr超能文献

罕见病药物再利用:罕见病群体的进展与机遇

Drug repurposing for rare: progress and opportunities for the rare disease community.

作者信息

Jonker Anneliene Hechtelt, O'Connor Daniel, Cavaller-Bellaubi Maria, Fetro Christine, Gogou Maria, 't Hoen Peter A C, de Kort Martin, Stone Heather, Valentine Nivedita, Pasmooij Anna Maria Gerdina

机构信息

Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Enschede, Netherlands.

International Rare Diseases Research Consortium, Paris, France.

出版信息

Front Med (Lausanne). 2024 Jan 17;11:1352803. doi: 10.3389/fmed.2024.1352803. eCollection 2024.

Abstract

Repurposing is one of the key opportunities to address the unmet rare diseases therapeutic need. Based on cases of drug repurposing in small population conditions, and previous work in drug repurposing, we analyzed the most important lessons learned, such as the sharing of clinical observations, reaching out to regulatory scientific advice at an early stage, and public-private collaboration. In addition, current upcoming trends in the field of drug repurposing in rare diseases were analyzed, including the role these trends could play in the rare diseases' ecosystem. Specifically, we cover the opportunities of innovation platforms, the use of real-world data, the use of artificial intelligence, regulatory initiatives in repurposing, and patient engagement throughout the repurposing project. The outcomes from these emerging activities will help progress the field of drug repurposing for the benefit of patients, public health and medicines development.

摘要

药物重新利用是满足罕见病未得到满足的治疗需求的关键机会之一。基于在小群体疾病中药物重新利用的案例以及先前在药物重新利用方面的工作,我们分析了汲取的最重要经验教训,例如临床观察结果的共享、尽早寻求监管科学建议以及公私合作。此外,还分析了罕见病药物重新利用领域当前即将出现的趋势,包括这些趋势在罕见病生态系统中可能发挥的作用。具体而言,我们涵盖了创新平台的机遇、真实世界数据的使用、人工智能的使用、重新利用方面的监管举措以及在整个重新利用项目中的患者参与。这些新兴活动的成果将有助于推动药物重新利用领域的发展,造福患者、公共卫生和药物研发。

相似文献

1
Drug repurposing for rare: progress and opportunities for the rare disease community.
Front Med (Lausanne). 2024 Jan 17;11:1352803. doi: 10.3389/fmed.2024.1352803. eCollection 2024.
3
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
Drug repurposing in rare diseases: Myths and reality.
Therapie. 2020 Apr;75(2):157-160. doi: 10.1016/j.therap.2020.02.006. Epub 2020 Feb 13.
5
International regulatory and publicly-funded initiatives to advance drug repurposing.
Front Med (Lausanne). 2024 May 31;11:1387517. doi: 10.3389/fmed.2024.1387517. eCollection 2024.
6
Drug repurposing for rare diseases.
Prog Mol Biol Transl Sci. 2024;207:231-247. doi: 10.1016/bs.pmbts.2024.03.034. Epub 2024 May 17.
7
Artificial intelligence in drug repurposing for rare diseases: a mini-review.
Front Med (Lausanne). 2024 May 22;11:1404338. doi: 10.3389/fmed.2024.1404338. eCollection 2024.
8
Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases.
Front Genet. 2021 Jul 28;12:707836. doi: 10.3389/fgene.2021.707836. eCollection 2021.
9
Drug Repurposing for Rare Diseases.
Trends Pharmacol Sci. 2021 Apr;42(4):255-267. doi: 10.1016/j.tips.2021.01.003. Epub 2021 Feb 6.
10
Drug repurposing in silico screening platforms.
Biochem Soc Trans. 2022 Apr 29;50(2):747-758. doi: 10.1042/BST20200967.

引用本文的文献

1
Advances in mass spectrometry of lipids for the investigation of Niemann-pick type C disease.
Lipids Health Dis. 2025 Jul 30;24(1):254. doi: 10.1186/s12944-025-02675-7.
2
Allosteric regulation of UBIAD1 trafficking from ER to Golgi revealed by chemical genetic screening.
Proc Natl Acad Sci U S A. 2025 May 20;122(20):e2426532122. doi: 10.1073/pnas.2426532122. Epub 2025 May 15.
3
Rare Disease Drug Repurposing.
JAMA Netw Open. 2025 May 1;8(5):e258330. doi: 10.1001/jamanetworkopen.2025.8330.
5
Using chanarin-dorfman syndrome patient fibroblasts to explore disease mechanisms and new treatment avenues.
Orphanet J Rare Dis. 2025 Apr 24;20(1):195. doi: 10.1186/s13023-025-03711-6.
6
7
Debates over orphan drug pricing: a meta-narrative literature review.
Orphanet J Rare Dis. 2025 Mar 7;20(1):107. doi: 10.1186/s13023-025-03634-2.
8
Rifampicin Repurposing Reveals Anti-Melanogenic Activity in B16F10 Melanoma Cells.
Molecules. 2025 Feb 15;30(4):900. doi: 10.3390/molecules30040900.
9
Effects of the Paediatric Regulation funding on the development of off-patent medicines in children.
Front Med (Lausanne). 2025 Jan 30;11:1473862. doi: 10.3389/fmed.2024.1473862. eCollection 2024.
10
Advances in the Repurposing and Blood-Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors.
Cancers (Basel). 2025 Jan 27;17(3):439. doi: 10.3390/cancers17030439.

本文引用的文献

1
IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases.
Nat Rev Drug Discov. 2023 Dec;22(12):937-938. doi: 10.1038/d41573-023-00168-9.
2
Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Genet Med. 2023 Dec;25(12):100969. doi: 10.1016/j.gim.2023.100969. Epub 2023 Aug 24.
3
Patients as research partners in preference studies: learnings from IMI-PREFER.
Res Involv Engagem. 2023 Apr 7;9(1):21. doi: 10.1186/s40900-023-00430-9.
4
A Path to Real-World Evidence in Critical Care Using Open-Source Data Harmonization Tools.
Crit Care Explor. 2023 Apr 3;5(4):e0893. doi: 10.1097/CCE.0000000000000893. eCollection 2023 Apr.
5
Drug Repurposing: An Effective Tool in Modern Drug Discovery.
Russ J Bioorg Chem. 2023;49(2):157-166. doi: 10.1134/S1068162023020139. Epub 2023 Feb 21.
6
Successful Treatment of Balamuthia mandrillaris Granulomatous Amebic Encephalitis with Nitroxoline.
Emerg Infect Dis. 2023 Jan;29(1):197-201. doi: 10.3201/eid2901.221531.
7
The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases.
Int J Mol Sci. 2022 Apr 11;23(8):4217. doi: 10.3390/ijms23084217.
8
Drug Repurposing for Rare Diseases: A Role for Academia.
Front Pharmacol. 2021 Oct 20;12:746987. doi: 10.3389/fphar.2021.746987. eCollection 2021.
9
-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib.
Front Pediatr. 2021 Sep 9;9:732836. doi: 10.3389/fped.2021.732836. eCollection 2021.
10
Drug Repurposing: Claiming the Full Benefit from Drug Development.
Curr Cardiol Rep. 2021 May 7;23(6):62. doi: 10.1007/s11886-021-01484-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验